Mesoblast (MESO): Prakiraan wutah bathi resik saben saham kanggo taun ngarep

Mesoblast Limited (MESO) generates revenue through the commercialization of cell-based products designed to treat cardiovascular pathologies. This chart of the consensus EPS n+1 forecast reflects market expectations, where the value 262.00 describes the current level. Production is partially automated, although the clinical stage requires expert oversight. The R&D cycle is currently completing the regulatory approval stage to bring breakthrough therapies to market.

Mesoblast Ltd (MESO): Prakiraan wutah bathi resik saben saham ing taun ngarep saka 04.07.2022 nganti 14.11.2026

Rincian metrik komprehensif lan analitis Mesoblast (MESO)

- rega saham lan konsensus proyeksi valuasi:

Rega saham Mesoblast Ltd|MESO - Rata-rata rega prakiraan

- data kapitalisasi bursa:

Nilai pasar Mesoblast Pharma|MESO - Rega Tumbas Perusahaan

- rincian nilai buku perusahaan:

Aset Bersih saben Siji Saham Mesoblast|MESO - Ekuitas Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku mesoblast.com|MESO - Aset Agregat Perusahaan

- data utang lan likuiditas:

Utang marang Ekuitas Mesoblast Limited|MESO - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Mesoblast Ltd|MESO - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Mesoblast Pharma|MESO - Gunggunge utang jangka dawa|Kewajiban jangka cendhak perusahaan Mesoblast|Indikator likuiditas cepet mesoblast.com

- data bathi resik lan rasio valuasi:

MESO - Bathi pungkasan|Bathi sing dikarepake Mesoblast Limited|MESO - Rasio rega marang bathi|Pangali Forward P/E Mesoblast Ltd|MESO - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Mesoblast Corp|MESO - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Mesoblast|MESO - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan mesoblast.com|MESO - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Mesoblast Limited

- data total pendapatan lan volume dodolan:

MESO - Total pendapatan perusahaan|Prakiraan volume dodolan Mesoblast|MESO - Rasio kapitalisasi marang pendapatan|Rasio rega marang prakiraan pendapatan Mesoblast Corp

Analisis dhasar perusahaan:MESO, mesoblast.com

Mesoblast Limited (MESO) achievements in cell therapy and partnerships with pharmaceutical behemoths determine future capitalization based on clinical trial results. The price action of the annual EPS growth for the next period reflects analysts' daily profit re-evaluations, where sharp fluctuations in the indicator signal rising business uncertainty, warning investors of potential risks of a deep asset drawdown.

Analisis pesaing

LCTX (lineagecell.com) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep surrozen.com|Prakiraan wutah bathi saben saham kanggo taun ngarep CCEL (Cryo-Cell International)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep FBLG (FibroBiologics Inc.)|Prakiraan wutah bathi kanggo taun ngarep LGVN (Longeveron Inc)|Dinamika bathi saben saham sing diarepake ing taun ngarep BRTX|CELZ: Prakiraan wutah bathi saben saham kanggo taun ngarep